Ruijter et al. evaluated a CD8-targeted one-armed antibody 89ZED88082A PET agent in 38 patients with a variety of cancers, including colorectal, cervical, melanoma, esophageal, HCC, ovarian, NSCLC, and TNBC, who were imaged 30 days before and 30 days after ICI treatment (66). The gene discussed is CD8A; the disease is melanoma.